Mederi Therapeutics launched of RFT3, the third generation of Stretta technology.
Here are five things to know:
1. The new Stretta RFT3 maintains the same procedure as the first two generations of Stretta, however its features aesthetic, functional, and material improvements.
2. Stretta technology is intended to help treat chronic those suffering from gastroesophageal reflux disease.
3. The new technology will be launched at Digestive Disease Week 2016, May 21-24 in San Diego.
4. At Digestive Disease Week, Mark Noar, MD, director of The Heartburn and Reflux Study Center in Towson, Md., will discuss 10-year follow-up data on Stretta from studies he conducted.
5. Mederi Therapeutics manufactures non-surgical devices that use non-ablative radiofrequency energy to treat digestive diseases.